There is no indication that covid-19 has a long-term effect on pregnancy, the mother's psychiatric condition, or the infant's developmental delay. Between May 1st and July 31st 2020, 72 pregnant patients with covid-19 took part in a study that took place in different locations. Since giving birth these woman patients engaged in three-month follow-up surveys. The data was collected from Covid-19 medical history, maternal reports, quarantine questionnaires, mother-baby feeding separation, and assessing the mothers psychiatric illnesses. While there is no conclusive evidence of vertical transmission of SARS-COV-2, in order to reduce the risk of infection, healthcare professionals and researchers must focus more on the mental health of pregnant women, infant feeding, and closeness to the parents. This will aid in the early development of the new born, reducing stress on the mother.

Background: Recently with the changes in population lifestyle, prediabetes is constantly on the rise. Management of prediabetes currently is with lifestyle modifications like weight loss, exercise and diet control. Better drugs with acceptable safety profile are needed for better control of prediabetes. This study was thus designed to evaluate the antihyperglycaemic effect of one such potential compound Syzygium cumini (SC) (Jamun)in comparison to conventional antidiabetic drug Metformin. Methods: Rats were divided into four study groups (SC 100mg/kg and 200 mg/kg, metformin 90 mg/kg and SC 200 mg/kg with metformin 90 mg/kg). The glycaemic changes were followed up for a period of 8 weeks. Results: Streptozotocin (STZ) induced significant rise in blood glucose levels in the rats. SC100 mg/kg and 200 mg/kg caused a reduction in BSL (192.50 ± 6.189 & 175.00 ± 6.782 respectively). SC 200 mg/kg alone and in combination with metformin caused a significant reduction in HbA1C levels at the end of 8th week (8.84 ± 0.65 &6.86 ± 0.40 respectively) as compared to their baseline levels. Increase in dose had led to more significant reduction in BSL at the end of 8th week in groups A & B (p < 0.05). However, reduction of BSL was superior with Metforminalone (159.17 ± 13.060) compared to Syzygium cumini administered alone. Also antihyperglycemic effect of Syzygium cumini administered along with metformin was significant (p < 0.05) compared to either doses of Syzygium cumini given alone. Conclusions: Syzygium cumini demonstratedantihyperglycemic activity in diabetic rats but less significant when compared to metformin. Antihyperglycaemic effect of Syzygium cumini with metformin was significantly better than either drugsgiven alone. In prediabetic or diabeticindividuals Syzygium cumini seed powdercan be suggested as a potential add-on therapy with conventional antidiabetic drugs. However more non-clinical and clinical studies need to be conducted to confirm the findings.

No abstract

No abstract

No abstract